SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (6030)11/20/2004 8:46:40 PM
From: Robohogs  Read Replies (1) | Respond to of 10345
 
That pricing would appear to hurt ELN for BIIB's benefit - yeah it reduces cannibalization by killing volume. That pricing would also kill cocktail therapy approach AND likely brings in more anti-drug company forces looking to fix the price. I would assume stock would crater at that pricing. I was hoping for high teens/low 20s.

Jon



To: fred hayes who wrote (6030)11/20/2004 11:33:49 PM
From: rkrw  Read Replies (1) | Respond to of 10345
 
Report cites conversations with biib mgt.

"Management indicated that pricing of Antegren will be a least 2X Avonex WAC, suggesting a price of $28K-$30K/year."

But I suppose biib reserves the right to change their mind.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News